NEWS
NEWS
NEWS
JEFF ARONIN CHAIRMAN AND CEO OF PARAGON BIOSCIENCES
January 11, 2019
As Chairman and CEO of Paragon Biosciences, Jeffrey Aronin has invested in and launched several successful portfolio companies, including: Harmony Biosciences, Castle Creek Pharma, Emalex Biosciences, and Skyline Biosciences. Previously, Mr. Aronin served as President and CEO of Ovation Pharmaceuticals, which he founded in 2000 and was acquired by Lundbeck in 2009.
When it comes to earning new drug approvals, Jeffrey Aronin’s companies have been among the most successful in the industry. For example, in neurology focus areas, no one has led the development of more FDA approved drugs than Jeffrey Aronin and his teams over the past 10 years.
Access the entire article here:
JEFF ARONIN CHAIRMAN AND CEO OF PARAGON BIOSCIENCES
January 11, 2019
As Chairman and CEO of Paragon Biosciences, Jeffrey Aronin has invested in and launched several successful portfolio companies, including: Harmony Biosciences, Castle Creek Pharma, Emalex Biosciences, and Skyline Biosciences. Previously, Mr. Aronin served as President and CEO of Ovation Pharmaceuticals, which he founded in 2000 and was acquired by Lundbeck in 2009.
When it comes to earning new drug approvals, Jeffrey Aronin’s companies have been among the most successful in the industry. For example, in neurology focus areas, no one has led the development of more FDA approved drugs than Jeffrey Aronin and his teams over the past 10 years.
Access the entire article here:
JEFF ARONIN CHAIRMAN AND CEO OF PARAGON BIOSCIENCES
January 11, 2019
As Chairman and CEO of Paragon Biosciences, Jeffrey Aronin has invested in and launched several successful portfolio companies, including: Harmony Biosciences, Castle Creek Pharma, Emalex Biosciences, and Skyline Biosciences. Previously, Mr. Aronin served as President and CEO of Ovation Pharmaceuticals, which he founded in 2000 and was acquired by Lundbeck in 2009.
When it comes to earning new drug approvals, Jeffrey Aronin’s companies have been among the most successful in the industry. For example, in neurology focus areas, no one has led the development of more FDA approved drugs than Jeffrey Aronin and his teams over the past 10 years.
Access the entire article here:
